[go: up one dir, main page]

GB201908233D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB201908233D0
GB201908233D0 GBGB1908233.8A GB201908233A GB201908233D0 GB 201908233 D0 GB201908233 D0 GB 201908233D0 GB 201908233 A GB201908233 A GB 201908233A GB 201908233 D0 GB201908233 D0 GB 201908233D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908233.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, MedImmune Ltd filed Critical ADC Therapeutics SA
Priority to GBGB1908233.8A priority Critical patent/GB201908233D0/en
Publication of GB201908233D0 publication Critical patent/GB201908233D0/en
Priority to CN202080042853.5A priority patent/CN114302745A/en
Priority to AU2020292965A priority patent/AU2020292965A1/en
Priority to KR1020227000169A priority patent/KR20220020332A/en
Priority to MX2021015403A priority patent/MX2021015403A/en
Priority to US17/617,875 priority patent/US20220305132A1/en
Priority to EP20733376.6A priority patent/EP3980079A1/en
Priority to SG11202113092WA priority patent/SG11202113092WA/en
Priority to JP2021573165A priority patent/JP7740994B2/en
Priority to CA3142645A priority patent/CA3142645A1/en
Priority to PCT/EP2020/065880 priority patent/WO2020249528A1/en
Priority to IL288716A priority patent/IL288716B1/en
Ceased legal-status Critical Current

Links

GBGB1908233.8A 2019-06-10 2019-06-10 Combination therapy Ceased GB201908233D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1908233.8A GB201908233D0 (en) 2019-06-10 2019-06-10 Combination therapy
PCT/EP2020/065880 WO2020249528A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
MX2021015403A MX2021015403A (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent.
AU2020292965A AU2020292965A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent
KR1020227000169A KR20220020332A (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or second-line agent
CN202080042853.5A CN114302745A (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-CD 19 antibody drug conjugate and a PI3K inhibitor or a second agent
US17/617,875 US20220305132A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
EP20733376.6A EP3980079A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
SG11202113092WA SG11202113092WA (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
JP2021573165A JP7740994B2 (en) 2019-06-10 2020-06-08 Combination Therapies Comprising Anti-CD19 Antibody Drug Conjugates and PI3K Inhibitors or Second-Line Agents
CA3142645A CA3142645A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
IL288716A IL288716B1 (en) 2019-06-10 2021-12-06 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908233.8A GB201908233D0 (en) 2019-06-10 2019-06-10 Combination therapy

Publications (1)

Publication Number Publication Date
GB201908233D0 true GB201908233D0 (en) 2019-07-24

Family

ID=67386094

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908233.8A Ceased GB201908233D0 (en) 2019-06-10 2019-06-10 Combination therapy

Country Status (1)

Country Link
GB (1) GB201908233D0 (en)

Similar Documents

Publication Publication Date Title
IL277336A (en) Combination therapy
GB201804255D0 (en) Macrophage-based therapy
GB201900702D0 (en) Therapy
GB201819853D0 (en) Therapy
ZA202200731B (en) Combination therapy
IL280729A (en) Combination therapy
IL279908A (en) Combination therapy
SG11202101518QA (en) Combination therapy
IL288237A (en) Combination therapy
GB201918752D0 (en) New therapy
GB201912191D0 (en) New therapy
GB201914006D0 (en) Combination Therapy
GB201910473D0 (en) Combination therapy
GB201906864D0 (en) Combination therapy
GB201817385D0 (en) Therapy
GB201919301D0 (en) Combination therapy
GB201917254D0 (en) Combination therapy
GB201908233D0 (en) Combination therapy
GB201908227D0 (en) Combination therapy
GB201908231D0 (en) Combination therapy
GB201908232D0 (en) Combination Therapy
GB201908234D0 (en) Combination therapy
GB201908225D0 (en) Combination therapy
GB201919036D0 (en) Therapy
GB201906873D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)